Significant Reduction In Rate Of Lung Function Decline Achieved In COPD Patients Receiving Seretide®/Advair®

Study results published show that treatment with Seretide®/Advair® (salmeterol/fluticasone propionate 50/500mcg) can slow the progression of Chronic Obstructive Pulmonary Disease (COPD) by significantly lowering a patient's rate of lung function decline compared with those receiving placebo. [1] This is the first time a treatment has been shown to slow the decline in lung function and impact progression of this serious lung disease, which accounts for more than 3 million deaths worldwide each year.[2]


The results showed that treatment can decrease the excess decline in lung function (measured by forced expiratory volume in 1 second [FEV1]) seen in patients with COPD by more than 50%, representing a significant slowing of disease progression. Those patients who received salmeterol/fluticasone propionate had a lower rate of decline in lung function compared to those who received placebo (39mL vs 55mL per year [p